Sailong Pharmaceutical Group Co (SZSE:002898) Risk Assessment

View and export this data going back to 2017. Start your Free Trial

What is Sailong Pharmaceutical Group Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Sailong Pharmaceutical Group Co is: Moderate Risk: Sensitive, better choose undervalued stock.

Competitive Comparison of Sailong Pharmaceutical Group Co's Risk Assessment

For the Biotechnology subindustry, Sailong Pharmaceutical Group Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sailong Pharmaceutical Group Co's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sailong Pharmaceutical Group Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Sailong Pharmaceutical Group Co's Risk Assessment falls into.

Sailong Pharmaceutical Group Co (SZSE:002898) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Sailong Pharmaceutical Group Co Risk Assessment Related Terms

Thank you for viewing the detailed overview of Sailong Pharmaceutical Group Co's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Sailong Pharmaceutical Group Co (SZSE:002898) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sailong Pharmaceutical Group Co Ltd (SZSE:002898) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 47, Haibin South Road, 2nd Floor, Everbright International Trade Center, Guangdong Province, Zhuhai, CHN, 519015

Website

http://www.sailong.cn

Zhuhai Sailong Pharmaceutical Co Ltd is the pharmaceutical company. It is mainly engaged in the development, production, marketing and technical services of pharmaceuticals. The company's products are mainly concentrated in the fields of the nervous system, cardiovascular and digestive system. The product range includes monosialin tetrahexose ganglioside sodium injections, brain protein hydrolyzate for injections, clindamycin phosphate for injections, pantoprazole sodium for injections and milrinon injections, among others.

Executives

Tang Lin	Director
Long Zhi Xiang	Director
Deng Yong Jun	Supervisors
Zhou Bei	Supervisors
Li Jian Feng	Directors, executives

Sailong Pharmaceutical Group Co (SZSE:002898) Headlines

No Headlines